NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company focused on antiviral drug development, has announced that its Phase II clinical trial of NV-387 Oral Gummies for the treatment of Bundibugyo Ebolavirus and other Ebola viruses is expected to commence soon in the Democratic Republic of Congo (DRC). The company has received regulatory approval from the local agency ACOREP and has appointed Professor Patrick Katoto as principal investigator. Preparatory activities, including staff training, are already underway, and the NV-387 drug product is available in the DRC, with first patient dosing anticipated within a few weeks, barring any outbreak-related impediments.
NV-387 is an orally administered broad-spectrum antiviral designed to mimic host-side features required by viruses for infection. NanoViricides believes that oral delivery could offer significant advantages in resource-limited outbreak settings compared to treatments requiring intravenous infusions. This is particularly relevant in the DRC, where healthcare infrastructure may be limited and oral administration could simplify logistics and improve patient compliance.
Om Sai Clinical Research Private Limited is serving as the contract research organization (CRO) for this Phase II trial, as well as for the company's planned Phase II trial of NV-387 Oral Gummies for the treatment of Mpox in the DRC. This dual-use potential underscores the broad-spectrum nature of the drug candidate.
The upcoming trial is a critical step for NanoViricides as it advances NV-387 through clinical development. The company's lead drug candidate, NV-387, is also being developed for other viral infections, including RSV, COVID-19, Long COVID, Influenza, and other respiratory viral infections, as well as Mpox and Measles. The company has a pipeline of other candidates, including NV-HHV-1 for Shingles, and is exploring treatments for a wide range of viral diseases such as herpes, viral eye infections, influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola.
The approval for this trial comes at a time when Ebola outbreaks remain a public health concern in Central Africa. The availability of an oral treatment could be a game-changer in managing outbreaks, especially in areas where access to medical facilities is challenging. The trial's success could pave the way for a more practical and scalable response to Ebola and other viral threats.
NanoViricides' technology is based on the TheraCour nanomedicine platform, which it licenses from TheraCour Pharma, Inc. The company holds exclusive, perpetual licenses for several drugs targeting specific human viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes, Influenza, Dengue, Japanese Encephalitis, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The company's business model relies on licensing technology from TheraCour for specific applications.
As with any pharmaceutical development, the path to approval is lengthy and requires substantial capital. NanoViricides acknowledges that there can be no assurance that its drug candidates will demonstrate sufficient effectiveness and safety in clinical trials. However, the initiation of this Phase II trial marks a significant milestone in the company's efforts to bring a new oral antiviral to market.
For more information about NanoViricides and its pipeline, visit the company's website at www.nanoviricides.com. The full press release is available at https://ibn.fm/uWVTo.
